Dr Michael Kalos | Chief Scientific Officer, Cancer Immunobiology
Eli Lilly and Co

Dr Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Co

Dr. Kalos joined Eli Lilly In October 2013. As a member of Lilly’s Research Oncology Division, Michael leads preclinical and translational efforts to develop a Cancer Immunotherapy Program at Eli Lilly. Current efforts are focused on establishing and steering preclinical development of the existing internal pipeline, establishing a robust and integrated program to discover and develop immunotherapy at Eli Lilly, and developing external relationships with key academic centers to augment internal expertise and capabilities.
Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy and biomarkers, with over 20 years experience in immunotherapy spanning biotech, academia, and big pharma. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, a member of institutional, and corporate scientific advisory boards, and is an active member of steering committees for international immunotherapy societies and working groups.


Agenda Day 1 @ 09:45

What can we learn from vaccine development for infectious diseases that can be applied to cancer and vice versa?

  • Bridging infectious disease vaccines with cancer immunotherapy
  • Technologies that are applicable to both including RNA vaccines
  • How to stimulate both humoral and cell-mediated immunity that are likely paramount for successful cancer immunotherapeutics
  • Understanding infectious vaccine approaches and immunological responses to strengthen cancer immunotherapeutic strategies

back to speakers